Edition:
United States

Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

17.00USD
25 Sep 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$17.00
Open
--
Day's High
--
Day's Low
--
Volume
2,300
Avg. Vol
3,723
52-wk High
$19.36
52-wk Low
$12.01

Chart for

About

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and... (more)

Overall

Beta: 0.93
Market Cap(Mil.): kr.3,358.86
Shares Outstanding(Mil.): 30.76
Dividend: --
Yield (%): --

Financials

  ZEAL.OQ Industry Sector
P/E (TTM): -- 109.17 32.94
EPS (TTM): -12.17 -- --
ROI: -95.66 1.47 12.84
ROE: -150.59 0.22 14.95

BRIEF-Zealand Pharma Announces Interim Report For The First Quarter Of 2018

* ZEALAND PHARMA - INTERIM REPORT FOR THE FIRST QUARTER OF 2018 Source text for Eikon: Further company coverage:

May 16 2018

BRIEF-Zealand Q1 Net Sales Of Soliqua 100/33 And Lyxumia/Adlyxin At EUR 14.5 Mln

* REG-ZEALAND ANNOUNCES NET SALES OF SOLIQUA® 100/33 AND LYXUMIA®/ADLYXIN® FOR THE FIRST QUARTER OF 2018

Apr 27 2018

BRIEF-Zealand Announces Successful End-Of-Phase 2 Meeting With FDA On Glepaglutide For Short Bowel Syndrome

* ZEALAND ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA ON GLEPAGLUTIDE FOR SHORT BOWEL SYNDROME

Apr 26 2018

BRIEF-Zealand And Roche Diabetes Care Enter Phase 3 Study Collaboration For Treatment Of Congenital Hyperinsulinism With Dasiglucagon

April 11 Zealand Pharma A/S - Co Is Responsible For Conducting Phase 3 Trials, While Roche Diabetes Care Provides Its Accu :

Apr 11 2018

BRIEF-Zealand Pharma Enters Collaboration Agreement With Roche Diabetes Care

* HAS ENTERED A COLLABORATION AGREEMENT WITH ROCHE DIABETES CARE

Apr 11 2018

Earnings vs. Estimates